Literature DB >> 12454561

Symptom severity and exclusion from antidepressant efficacy trials.

Mark Zimmerman1, Michael A Posternak, Iwona Chelminski.   

Abstract

It is the standard practice in antidepressant efficacy trials (AETs) to exclude potential participants with major depressive disorder (MDD) who score below a threshold on the Hamilton Rating Scale for Depression (HAM-D). It is unknown to what extent various cutoff scores impact on the generalizability of these trials. In the present report, we sought to determine how many patients with MDD presenting to an outpatient practice would fail to qualify for an AET because their symptoms were not sufficiently severe, and to what extent the variability in HAM-D cutoff scores impacts exclusion rates. Fifteen hundred individuals presenting for an intake at a psychiatric outpatient practice underwent an evaluation with semistructured diagnostic interviews. Five hundred and three patients received a principal diagnosis of nonbipolar, nonpsychotic MDD. Thirty-nine AETs published in five leading journals during the past 7 years were reviewed, 36 of which required a minimum score on the HAM-D for inclusion. We applied the HAM-D cutoffs used in these AETs to the 503 depressed patients to determine how many would qualify for each AET. Based on the least and most restrictive cutoff scores, between 11.3% and 71.0% of the depressed patients from our practice had an insufficient HAM-D score to qualify for an AET. The two most commonly used cutoff scores would lead to the exclusion of almost half of our sample. AETs tend to include the subset of depressed individuals with moderate to severe MDD and exclude a significant proportion of depressed patients who have mild MDD. The implications of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12454561     DOI: 10.1097/00004714-200212000-00011

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  9 in total

1.  The treatment of minor depression with St. John's Wort or citalopram: failure to show benefit over placebo.

Authors:  Mark Hyman Rapaport; Andrew A Nierenberg; Robert Howland; Christina Dording; Pamela J Schettler; David Mischoulon
Journal:  J Psychiatr Res       Date:  2011-05-31       Impact factor: 4.791

2.  'They won't do any harm and might do some good': time to think again on the use of antidepressants?

Authors:  Hugh Middleton; Joanna Moncrieff
Journal:  Br J Gen Pract       Date:  2011-01       Impact factor: 5.386

Review 3.  Conducting clinical research in community mental health settings: Opportunities and challenges.

Authors:  Oleg V Tcheremissine; Whitney E Rossman; Manuel A Castro; Dineen R Gardner
Journal:  World J Psychiatry       Date:  2014-09-22

4.  Exploration of a Biblical Counseling Program for Depression.

Authors:  Denise Ogorek; Janalee Isaacson
Journal:  J Relig Health       Date:  2021-02-27

5.  A randomized controlled trial of venlafaxine XR for major depressive disorder after spinal cord injury: Methods and lessons learned.

Authors:  Charles H Bombardier; Jesse R Fann; Catherine S Wilson; Allen W Heinemann; J Scott Richards; Ann Marie Warren; Larry Brooks; Catherine A Warms; Nancy R Temkin; Denise G Tate
Journal:  J Spinal Cord Med       Date:  2013-11-26       Impact factor: 1.985

Review 6.  Antidepressant drug effects and depression severity: a patient-level meta-analysis.

Authors:  Jay C Fournier; Robert J DeRubeis; Steven D Hollon; Sona Dimidjian; Jay D Amsterdam; Richard C Shelton; Jan Fawcett
Journal:  JAMA       Date:  2010-01-06       Impact factor: 56.272

7.  The drugs don't work? antidepressants and the current and future pharmacological management of depression.

Authors:  Elizabeth Penn; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2012-10

8.  Is placebo useful in the treatment of major depression in clinical practice?

Authors:  Carlo Marchesi; Chiara De Panfilis; Matteo Tonna; Paolo Ossola
Journal:  Neuropsychiatr Dis Treat       Date:  2013-06-25       Impact factor: 2.570

9.  Problems with using mechanisms to solve the problem of extrapolation.

Authors:  Jeremy Howick; Paul Glasziou; Jeffrey K Aronson
Journal:  Theor Med Bioeth       Date:  2013-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.